+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
New

Microbial Fermentation Contract Manufacturing Organization (CMO) - Global Strategic Business Report

  • PDF Icon

    Report

  • 378 Pages
  • July 2025
  • Region: Global
  • Global Industry Analysts, Inc
  • ID: 6106819
The global market for Microbial Fermentation Contract Manufacturing Organization (CMO) was estimated at US$3.7 Billion in 2024 and is projected to reach US$5.3 Billion by 2030, growing at a CAGR of 6.3% from 2024 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions. The report includes the most recent global tariff developments and how they impact the Microbial Fermentation Contract Manufacturing Organization (CMO) market.

Global Microbial Fermentation Contract Manufacturing Organization (CMO) Market - Key Trends & Drivers Summarized

How Is Microbial Fermentation CMO Shaping the Future of Biomanufacturing?

Microbial fermentation CMOs are playing an increasingly pivotal role in advancing biomanufacturing across industries ranging from pharmaceuticals and biotechnology to food, agriculture, and industrial chemicals. These specialized service providers offer outsourced fermentation capabilities that help companies scale production without the need to invest heavily in in-house infrastructure. Using microbes such as bacteria, yeast, or fungi, CMOs can produce a wide range of biologics, enzymes, proteins, peptides, antibiotics, and specialty ingredients. As the complexity of bioproducts continues to increase, CMOs bring not only fermentation capacity but also deep expertise in strain optimization, process development, and downstream purification. Their ability to operate under strict regulatory standards and adhere to current Good Manufacturing Practices (cGMP) makes them essential partners for companies navigating complex regulatory landscapes. The demand for contract fermentation services is also rising due to the surging interest in sustainable and bio-based production methods that replace traditional petrochemical approaches. Many biotechnology startups rely heavily on CMOs to accelerate time-to-market, enabling them to focus on innovation while outsourcing the technical and operational challenges of scale-up. Furthermore, CMOs are investing in flexible bioreactor systems and single-use technologies to support rapid transition between different microbial products and reduce contamination risks. The shift toward decentralized manufacturing and global supply chain resilience is further boosting the importance of microbial fermentation CMOs, who can provide localized or multi-site production strategies. As innovation in synthetic biology and metabolic engineering introduces novel strains and complex bioprocesses, CMOs are becoming strategic partners in translating lab-scale discoveries into commercially viable products.

Why Is Outsourcing Microbial Fermentation Gaining Traction Among Biotech and Pharma Companies?

The outsourcing of microbial fermentation is gaining significant momentum as biopharmaceutical and biotech companies seek to optimize resources, reduce risks, and scale faster in an increasingly competitive environment. For early-stage companies, building in-house fermentation facilities requires substantial capital investment, technical talent, and regulatory readiness, all of which can be overwhelming when timelines and budgets are tight. CMOs provide a turnkey solution that includes everything from strain development and fermentation scale-up to purification, quality control, and regulatory documentation. This comprehensive support allows innovators to focus on R&D and product development while leveraging the CMO's manufacturing infrastructure and operational expertise. Larger pharmaceutical companies are also expanding their use of CMOs to manage capacity constraints, address demand fluctuations, and maintain business continuity. The growing complexity of microbial expression systems, including the use of engineered strains for difficult-to-express proteins or high-value enzymes, has made access to experienced fermentation specialists more important than ever. Additionally, CMOs offer the flexibility to produce small, medium, or large batch sizes depending on clinical trial phases or commercial demand, ensuring scalability without the need for long-term fixed overhead. With biomanufacturing facilities often operating close to full capacity, outsourcing provides a strategic buffer to avoid production delays. Regulatory pressures and the need for global compliance have also made CMOs with strong regulatory track records particularly attractive. By outsourcing microbial fermentation, companies are not only optimizing cost structures but also gaining access to specialized knowledge, validated facilities, and quality assurance protocols that meet international standards.

How Are Technological Innovations Enhancing Microbial Fermentation Capabilities at CMOs?

Technological advancements are significantly enhancing the microbial fermentation capabilities of CMOs, driving improvements in efficiency, yield, product quality, and time-to-market. Innovations in synthetic biology and metabolic engineering are enabling the design of high-performance microbial strains that produce greater titers of target molecules with fewer byproducts. CMOs are increasingly integrating these technologies into their strain development and process optimization services to offer differentiated solutions tailored to client needs. Automated high-throughput screening and real-time process analytics are being used to monitor fermentation conditions and fine-tune production parameters with precision, improving reproducibility and scalability. In addition, advanced bioreactor systems with enhanced control of pH, temperature, dissolved oxygen, and agitation rates are allowing more consistent and optimized fermentation environments. Single-use bioreactors and closed-system designs are also gaining popularity, as they minimize cleaning validation requirements and reduce the risk of cross-contamination between batches. Downstream processing is benefiting from improvements in chromatography resins, membrane filtration, and centrifugation techniques that enhance the recovery and purity of microbial products. Digital twins and process modeling tools are now being used to simulate and refine manufacturing protocols, cutting down on development timelines and increasing first-time-right outcomes. Data integration and manufacturing execution systems (MES) are helping CMOs monitor batch performance, ensure traceability, and maintain regulatory compliance in real time. The adoption of Industry 4.0 principles, including machine learning and predictive maintenance, is further improving operational efficiency and product consistency. These technological capabilities are positioning CMOs as innovation hubs that can offer not just capacity, but cutting-edge biomanufacturing solutions tailored for the next generation of biologics and industrial bioproducts.

What Are the Main Drivers Behind the Growing Global Demand for Microbial Fermentation CMOs?

The growth in the microbial fermentation contract manufacturing organization market is driven by several converging trends in biotechnology, pharmaceutical development, consumer preferences, and global manufacturing strategies. One of the most significant drivers is the rising demand for biologics, biosimilars, and specialty enzymes, all of which increasingly rely on microbial fermentation for production. As the global healthcare sector shifts toward personalized medicine and targeted therapies, there is a greater need for specialized proteins and microbial-derived ingredients that require expert manufacturing capabilities. Additionally, the expansion of green chemistry and the bioeconomy is prompting industrial manufacturers to replace petrochemical processes with microbial fermentation pathways, creating new demand in sectors like agriculture, cosmetics, food, and biofuels. Regulatory and cost pressures are encouraging companies to outsource production rather than build and maintain dedicated facilities, especially when navigating the complex compliance frameworks of agencies such as the FDA, EMA, and PMDA. Furthermore, the globalization of clinical trials and product launches is creating a need for CMOs that offer multi-regional capabilities and quality systems aligned with international standards. The growth of emerging biotech hubs in Asia-Pacific, Latin America, and Eastern Europe is also expanding the client base for microbial fermentation services, as companies in these regions look for scalable, compliant, and technically advanced production partners. Strategic collaborations between CMOs, biotech startups, and research institutions are leading to faster development timelines and more efficient commercialization pathways. Finally, the rise in demand for pandemic preparedness and vaccine infrastructure has highlighted the importance of flexible and responsive microbial fermentation platforms, making CMOs a critical component of global health security and industrial innovation.

Scope Of Study:

The report analyzes the Microbial Fermentation Contract Manufacturing Organization (CMO) market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments: Expression System (Bacterial Expression Systems, Yeast Expression Systems, Other Expression Systems); Biologics (Enzyme Biologics, Antibodies Biologics, Plasmid DNA Biologics, Recombinant Proteins Biologics, Other Biologics); End-Use (Biopharma Companies End-Use, Academic & Research Institutes End-Use, Other End-Uses)

Geographic Regions/Countries: World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Key Insights:

  • Market Growth: Understand the significant growth trajectory of the Bacterial Expression Systems segment, which is expected to reach US$3.1 Billion by 2030 with a CAGR of a 5.5%. The Yeast Expression Systems segment is also set to grow at 7.2% CAGR over the analysis period.
  • Regional Analysis: Gain insights into the U.S. market, estimated at $1.0 Billion in 2024, and China, forecasted to grow at an impressive 9.7% CAGR to reach $1.1 Billion by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.

Why You Should Buy This Report:

  • Detailed Market Analysis: Access a thorough analysis of the Global Microbial Fermentation Contract Manufacturing Organization (CMO) Market, covering all major geographic regions and market segments.
  • Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
  • Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global Microbial Fermentation Contract Manufacturing Organization (CMO) Market.
  • Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.

Key Questions Answered:

  • How is the Global Microbial Fermentation Contract Manufacturing Organization (CMO) Market expected to evolve by 2030?
  • What are the main drivers and restraints affecting the market?
  • Which market segments will grow the most over the forecast period?
  • How will market shares for different regions and segments change by 2030?
  • Who are the leading players in the market, and what are their prospects?

Report Features:

  • Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2024 to 2030.
  • In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
  • Company Profiles: Coverage of players such as AbbVie Contract Manufacturing, AGC Biologics, AMRI (Albany Molecular), Arranta Bio (a Recipharm company), Boehringer Ingelheim BioXcellence and more.
  • Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.

Some of the 39 companies featured in this Microbial Fermentation Contract Manufacturing Organization (CMO) market report include:

  • AbbVie Contract Manufacturing
  • AGC Biologics
  • AMRI (Albany Molecular)
  • Arranta Bio (a Recipharm company)
  • Boehringer Ingelheim BioXcellence
  • Charles River Laboratories
  • Curia Global
  • CordenPharma
  • Fermic S.A. de C.V.
  • FUJIFILM Diosynth Biotechnologies
  • Ginkgo Bioworks
  • Kaneka Eurogentec
  • Kemwell Biopharma
  • Lonza Group
  • MicroSynbiotiX
  • Novasep
  • ProBioGen AG
  • Samsung Biologics
  • Syngene International
  • WuXi Biologics

This edition integrates the latest global trade and economic shifts as of June 2025 into comprehensive market analysis. Key updates include:

  • Tariff and Trade Impact: Insights into global tariff negotiations across 180+ countries, with analysis of supply chain turbulence, sourcing disruptions, and geographic realignment. Special focus on 2025 as a pivotal year for trade tensions, including updated perspectives on the Trump-era tariffs.
  • Adjusted Forecasts and Analytics: Revised global and regional market forecasts through 2030, incorporating tariff effects, economic uncertainty, and structural changes in globalization. Includes segmentation by product, technology, type, material, distribution channel, application, and end-use, with historical analysis since 2015.
  • Strategic Market Dynamics: Evaluation of revised market prospects, regional outlooks, and key economic indicators such as population and urbanization trends.
  • Innovation & Technology Trends: Latest developments in product and process innovation, emerging technologies, and key industry drivers shaping the competitive landscape.
  • Competitive Intelligence: Updated global market share estimates for 2025, competitive positioning of major players (Strong/Active/Niche/Trivial), and refined focus on leading global brands and core players.
  • Expert Insight & Commentary: Strategic analysis from economists, trade experts, and domain specialists to contextualize market shifts and identify emerging opportunities.
  • Complimentary Update: Buyers receive a free July 2025 update with finalized tariff impacts, new trade agreement effects, revised projections, and expanded country-level coverage.

Table of Contents

I. METHODOLOGYII. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Tariff Impact on Global Supply Chain Patterns
  • Microbial Fermentation Contract Manufacturing Organization (CMO) - Global Key Competitors Percentage Market Share in 2025 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
  • Surging Demand for Biologics and Alternative Proteins Throws the Spotlight on Microbial Fermentation CMOs
  • Biopharma Outsourcing Trends Drive Adoption of Scalable and Flexible Fermentation Manufacturing Services
  • Rise of Synthetic Biology and Engineered Microbes Spurs Growth in Specialized Fermentation Capabilities
  • Expansion of Microbiome-Based Therapeutics Strengthens the Business Case for Niche-Expertise CMOs
  • Nutraceutical and Functional Ingredient Boom Generates Demand for Food-Grade Fermentation Facilities
  • Capacity Constraints at In-House Biomanufacturing Sites Accelerate Partnerships with Fermentation CMOs
  • Advancements in Downstream Purification Technologies Enhance Efficiency and Throughput of CMO Operations
  • Increasing Complexity of Strain Development Here`s How it Drives Demand for End-to-End CMO Solutions
  • Rapid Growth in Cell-Free Protein Synthesis Expands Addressable Markets for Agile Fermentation Players
  • Globalization of Biotech Pipelines Spurs Regional Demand for Localized Fermentation Manufacturing Services
  • Environmental and Cost Pressures Drive Innovation in Low-Waste, Energy-Efficient Fermentation Processes
  • Convergence of AI and Bioprocessing Platforms Generates Opportunities for Smarter and Faster Fermentation Scale-Up
4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Microbial Fermentation Contract Manufacturing Organization (CMO) Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for Microbial Fermentation Contract Manufacturing Organization (CMO) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 3: World Historic Review for Microbial Fermentation Contract Manufacturing Organization (CMO) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 4: World 16-Year Perspective for Microbial Fermentation Contract Manufacturing Organization (CMO) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2025 & 2030
  • TABLE 5: World Recent Past, Current & Future Analysis for Bacterial Expression Systems by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 6: World Historic Review for Bacterial Expression Systems by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 7: World 16-Year Perspective for Bacterial Expression Systems by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for Yeast Expression Systems by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 9: World Historic Review for Yeast Expression Systems by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 10: World 16-Year Perspective for Yeast Expression Systems by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 11: World Recent Past, Current & Future Analysis for Other Expression Systems by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 12: World Historic Review for Other Expression Systems by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 13: World 16-Year Perspective for Other Expression Systems by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 14: World Recent Past, Current & Future Analysis for Academic & Research Institutes End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 15: World Historic Review for Academic & Research Institutes End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 16: World 16-Year Perspective for Academic & Research Institutes End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 17: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 18: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 19: World 16-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 20: World Recent Past, Current & Future Analysis for Biopharma Companies End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 21: World Historic Review for Biopharma Companies End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 22: World 16-Year Perspective for Biopharma Companies End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 23: World Recent Past, Current & Future Analysis for Enzyme Biologics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 24: World Historic Review for Enzyme Biologics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 25: World 16-Year Perspective for Enzyme Biologics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 26: World Recent Past, Current & Future Analysis for Antibodies Biologics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 27: World Historic Review for Antibodies Biologics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 28: World 16-Year Perspective for Antibodies Biologics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 29: World Recent Past, Current & Future Analysis for Plasmid DNA Biologics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 30: World Historic Review for Plasmid DNA Biologics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 31: World 16-Year Perspective for Plasmid DNA Biologics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 32: World Recent Past, Current & Future Analysis for Recombinant Proteins Biologics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 33: World Historic Review for Recombinant Proteins Biologics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 34: World 16-Year Perspective for Recombinant Proteins Biologics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 35: World Recent Past, Current & Future Analysis for Other Biologics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 36: World Historic Review for Other Biologics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 37: World 16-Year Perspective for Other Biologics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
III. MARKET ANALYSIS
UNITED STATES
  • Microbial Fermentation Contract Manufacturing Organization (CMO) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
CANADA
JAPAN
  • Microbial Fermentation Contract Manufacturing Organization (CMO) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
CHINA
  • Microbial Fermentation Contract Manufacturing Organization (CMO) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
EUROPE
  • Microbial Fermentation Contract Manufacturing Organization (CMO) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
FRANCE
  • Microbial Fermentation Contract Manufacturing Organization (CMO) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
GERMANY
  • Microbial Fermentation Contract Manufacturing Organization (CMO) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
ITALY
UNITED KINGDOM
  • Microbial Fermentation Contract Manufacturing Organization (CMO) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
SPAINRUSSIAREST OF EUROPE
ASIA-PACIFIC
  • Microbial Fermentation Contract Manufacturing Organization (CMO) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
AUSTRALIA
  • Microbial Fermentation Contract Manufacturing Organization (CMO) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
INDIA
  • Microbial Fermentation Contract Manufacturing Organization (CMO) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
SOUTH KOREAREST OF ASIA-PACIFIC
LATIN AMERICA
  • Microbial Fermentation Contract Manufacturing Organization (CMO) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
ARGENTINABRAZILMEXICOREST OF LATIN AMERICA
MIDDLE EAST
  • Microbial Fermentation Contract Manufacturing Organization (CMO) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
IRANISRAELSAUDI ARABIAUNITED ARAB EMIRATESREST OF MIDDLE EAST
AFRICA
  • Microbial Fermentation Contract Manufacturing Organization (CMO) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
IV. COMPETITION

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • AbbVie Contract Manufacturing
  • AGC Biologics
  • AMRI (Albany Molecular)
  • Arranta Bio (a Recipharm company)
  • Boehringer Ingelheim BioXcellence
  • Charles River Laboratories
  • Curia Global
  • CordenPharma
  • Fermic S.A. de C.V.
  • FUJIFILM Diosynth Biotechnologies
  • Ginkgo Bioworks
  • Kaneka Eurogentec
  • Kemwell Biopharma
  • Lonza Group
  • MicroSynbiotiX
  • Novasep
  • ProBioGen AG
  • Samsung Biologics
  • Syngene International
  • WuXi Biologics

Table Information